Article
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Disease models & mechanisms - 1 Sept 2016
Guan J, Tucker E R, Wan H, Chand D, Danielson L S, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson S P, Johnson T W, Smeal T, Martinsson T, Chesler L, Palmer R H, Hallberg B
Abstract excerpt
The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in the ALK kinase domain are typically refractory to crizotinib treatment, highlighting the need for more potent inhibitors. The next-generation ALK inhibitor PF-06463922 is predicted to exhibit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.